The Toronto Stock Exchange reports that Medexus Pharmaceuticals Inc.'s 6 per cent unsecured convertible debentures will be halted at the open on Oct. 16, 2023, and will be delisted at the close on the same day. According to the TSX, the debentures will mature on Oct. 16, 2023. The repayment price at maturity will be $1,282.71232877 per $1,000 principal amount, representing $1,250 per $1,000 principal amount and $32.71232877 for accrued and unpaid interest thereon to, but excluding, the maturity date.

The TSX notes that the holders of the debentures have the option to convert their debentures into units of the company, with each unit consisting of one common share of the company and one-half of one unlisted common share purchase warrant, at $6.30 per unit, until 5 p.m. Eastern Time on Oct. 13, 2023. Buyers of debentures who wish to exercise their conversion right should make their purchases sufficiently in advance of the deadline indicated in the relevant CDS bulletin, allowing for adequate time for settlement.

According to the TSX, debentureholders holding their interest beneficially through CDS need not take any action to receive the payment price on maturity. Registered holders must surrender their certificates to Computershare Trust Company of Canada at its principal offices in Calgary to receive the payment price on maturity. Trades in the debentures on Oct. 12, 2023, and Oct. 13, 2023, will settle on Oct. 13, 2023.